Left atrial appendage occlusion: Single center experience with PLAATO LAA Occlusion System® and AMPLATZER™ Cardiac Plug

Journal of Cardiology

Volumn 62, Issue 1, 2013, Pages 44-49

  Helsen, Frederik ^a   Nuyens, Dieter ^a   De Meester, Pieter ^a   Rega, Filip ^a   Budts, Werner ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Atrial fibrillation; Implants; Interventional cardiology; Left atrial appendage closure; Thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ADULT; AGED; AMPLATZER VASCULAR PLUG; ARTICLE; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GOLD STANDARD; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HUMAN; LEFT ATRIAL APPENDAGE CLOSURE DEVICE; MALE; PATIENT SAFETY; PATIENT SELECTION; POSTOPERATIVE COMPLICATION; RETROSPECTIVE STUDY; SCORING SYSTEM; THROMBOEMBOLISM;

ATRIAL FIBRILLATION; IMPLANTS; INTERVENTIONAL CARDIOLOGY; LEFT ATRIAL APPENDAGE CLOSURE; THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; FEASIBILITY STUDIES; FEMALE; HEART ATRIA; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SEPTAL OCCLUDER DEVICE; TREATMENT OUTCOME;

EID: 84880041046     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2013.02.019     Document Type: Article

References (37)

1. Go A.S., Hylek E.M., Phillips K.A., Chang Y., Henault L.E., Selby J.V., Singer D.E. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001, 285:2370-2375.
2. Miyasaka Y., Barnes M.E., Gersh B.J., Cha S.S., Bailey K.R., Abhayaratna W.P., Seward J.B., Tsang T.S. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006, 114:119-125.
3. Inoue H. Thromboembolism in patients with nonvalvular atrial fibrillation: comparison between Asian and Western countries. J Cardiol 2013, 61:1-7.
4. Camm A.J., Lip G.Y., De Caterina R., Savelieva I., Atar D., Hohnloser S.H., Hindricks G., Kirchhof P. ESC Committee for Practice Guidelines-CPG; Document Reviewers, 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012, 14:1385-1413.
5. Atarashi H., Inoue H., Okumura K., Yamashita T., Origasa H., Investigators J-RR Investigation of optimal anticoagulation strategy for stroke prevention in Japanese patients with atrial fibrillation-the J-RHYTHM Registry study design. J Cardiol 2011, 57:95-99.
6. Pisters R., Lane D.A., Nieuwlaat R., de Vos C.B., Crijns H.J., Lip G.Y. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010, 138:1093-1100.
7. Friberg L., Rosenqvist M., Lip G.Y. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012, 33:1500-1510.
8. Gage B.F., Boechler M., Doggette A.L., Fortune G., Flaker G.C., Rich M.W., Radford M.J. Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. Stroke 2000, 31:822-827.
9. Bungard T.J., Ghali W.A., Teo K.K., McAlister F.A., Tsuyuki R.T. Why do patients with atrial fibrillation not receive warfarin?. Arch Intern Med 2000, 160:41-46.
10. van Walraven C., Jennings A., Oake N., Fergusson D., Forster A.J. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 2006, 129:1155-1166.
11. Banerjee A., Lane D.A., Torp-Pedersen C., Lip G.Y. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost 2012, 107:584-589.
12. Larsen W.J., Serman L.S. Human embryology, vol. XIX 2001, Churchill Livingstone, New York, p. 548. 3rd ed.
13. Blackshear J.L., Odell J.A. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996, 61:755-759.
14. Healey J.S., Crystal E., Lamy A., Teoh K., Semelhago L., Hohnloser S.H., Cybulsky I., Abouzahr L., Sawchuck C., Carroll S., Morillo C., Kleine P., Chu V., Lonn E., Connolly S.J. Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. Am Heart J 2005, 150:288-293.
15. Kanderian A.S., Gillinov A.M., Pettersson G.B., Blackstone E., Klein A.L. Success of surgical left atrial appendage closure: assessment by transesophageal echocardiography. J Am Coll Cardiol 2008, 52:924-929.
16. Katz E.S., Tsiamtsiouris T., Applebaum R.M., Schwartzbard A., Tunick P.A., Kronzon I. Surgical left atrial appendage ligation is frequently incomplete: a transesophageal echocardiograhic study. J Am Coll Cardiol 2000, 36:468-471.
17. Ailawadi G., Gerdisch M.W., Harvey R.L., Hooker R.L., Damiano R.J., Salamon T., Mack M.J. Exclusion of the left atrial appendage with a novel device: early results of a multicenter trial. J Thorac Cardiovasc Surg 2011, 142:1002-1009. 9.e1.
18. Block P.C., Burstein S., Casale P.N., Kramer P.H., Teirstein P., Williams D.O., Reisman M. Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study. JACC Cardiovasc Interv 2009, 2:594-600.
19. Holmes D.R., Reddy V.Y., Turi Z.G., Doshi S.K., Sievert H., Buchbinder M., Mullin C.M., Sick P., PROTECT AF Investigators Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009, 374:534-542.
20. Park J.W., Bethencourt A., Sievert H., Santoro G., Meier B., Walsh K., Lopez-Minquez J.R., Meerkin D., Valdés M., Ormerod O., Leithäuser B. Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience. Catheter Cardiovasc Interv 2011, 77:700-706.
21. Bartus K., Han F.T., Bednarek J., Myc J., Kapelak B., Sadowski J., et al. Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience. J Am Coll Cardiol 2012, (September). [Epub ahead of print].
22. Gage B.F., Waterman A.D., Shannon W., Boechler M., Rich M.W., Radford M.J. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001, 285:2864-2870.
23. Lip G.Y., Nieuwlaat R., Pisters R., Lane D.A., Crijns H.J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010, 137:263-272.
24. Olesen J.B., Lip G.Y., Hansen M.L., Hansen P.R., Tolstrup J.S., Lindhardsen J., Selmer C., Ahlehoff O., Olsen A.M., Gislason G.H., Torp-Pedersen C. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011, 342:d124.
25. Hart R.G., Pearce L.A., Aguilar M.I., Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007, 146:857-867.
26. Ostermayer S.H., Reisman M., Kramer P.H., Matthews R.V., Gray W.A., Block P.C., Omran H., Bartorelli A.L., Della Bella P., Di Mario C., Pappone C., Casale P.N., Moses J.W., Poppas A., Williams D.O., et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. J Am Coll Cardiol 2005, 46:9-14.
27. Lip G.Y., Frison L., Halperin J.L., Lane D.A. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 2010, 41:2731-2738.
28. Stöllberger C., Schneider B., Finsterer J. Elimination of the left atrial appendage to prevent stroke or embolism? Anatomic, physiologic, and pathophysiologic considerations. Chest 2003, 124:2356-2362.
29. Reddy V.Y., Holmes D., Doshi S.K., Neuzil P., Kar S. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation 2011, 123:417-424.
30. Gangireddy S.R., Halperin J.L., Fuster V., Reddy V.Y. Percutaneous left atrial appendage closure for stroke prevention in patients with atrial fibrillation: an assessment of net clinical benefit. Eur Heart J 2012, 33:2700-2708.
31. Pugh D., Pugh J., Mead G.E. Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. Age Ageing 2011, 40:675-683.
32. Donzé J., Clair C., Hug B., Rodondi N., Waeber G., Cornuz J., Aujesky D. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med 2012, 125:773-778.
33. Connolly S.J., Ezekowitz M.D., Yusuf S., Eikelboom J., Oldgren J., Parekh A., Pogue J., Reilly P.A., Themeles E., Varrone J., Wang S., Alings M., Xavier D., Zhu J., Diaz R., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
34. Granger C.B., Alexander J.H., McMurray J.J., Lopes R.D., Hylek E.M., Hanna M., Al-Khalidi H.R., Ansell J., Atar D., Avezum A., Bahit M.C., Diaz R., Easton J.D., Ezekowitz J.A., Flaker G., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365:981-992.
35. Patel M.R., Mahaffey K.W., Garg J., Pan G., Singer D.E., Hacke W., Breithardt G., Halperin J.L., Hankey G.J., Piccini J.P., Becker R.C., Nessel C.C., Paolini J.F., Berkowitz S.D., Fox K.A., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-891.
36. Granger C.B., Armaganijan L.V. Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism. Circulation 2012, 125:159-164.
37. Ansell J. New oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation. Circulation 2012, 125:165-170.